March 2012 Issue
We have a ways to go before any kind of equilibrium is established in the pharma workforce, the job market guru says.
Sometimes, analytical methods, including NIR, just arent enough.
Now that emerging pharma markets are tightening their grip on quality, are U.S. manufacturers losing theirs?
The temptation to revert to old habits will be tested, but must be avoided.
Wishing wont move pharma from a tribal to a diverse, crossfunctional culture.
Large-scale benchmarking and local intervention allowed one manufacturer to diagnose network performance in three months.
Assessing the cost of poor quality doesnt just prevent disasters; its good for business.
Our eighth annual Job Satisfaction and Salary Survey says the big picture is brighter, though not clearer.
Pfizer director and PDA member Repetto discusses PDAs upcoming technical report and other critical issues facing SUS.
Quality management is part of an increased focus on productivity and performance.
Regulation and technology lead the fight against counterfeit pharmaceuticals.
Allied with other imaging techniques, Raman spectroscopy is being used for more QC, process control, and QbD efforts.
It is worth having dreams, and worth fulfilling them, says former Novartis employee Anna Kroczak.
Big pharma digital marketing campaigns are plowing full steam ahead, helping both consumers and patients, even without any clear guidance from FDA.
West and Vetter look to meet the needs of parenteral manufacturers demanding new, safer syringe options.
New designs save space
A look at whats new for the cleanroom set.